UWM
RNTX

Urban Wealth Management’s Rein Therapeutics RNTX Stock Holding History

Urban Wealth Management’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$10K Buy
+1,866
New +$17.1K 0.03% 204

Other funds holding RNTX

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
TCA
Taconic Capital Advisors New York $229M AUM 110.07% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Urban Wealth Management's RNTX Position: Q2 2022 in Review

Urban Wealth Management opened a new position in Rein Therapeutics (RNTX) in Q2 2022: 1,866 shares worth $10K. The stake represents 0.03% of the portfolio and ranks #204 among its holdings.

37 funds tracked by Wall St. Rank hold RNTX as of Q2 2022.

  • Urban Wealth Management held 1,866 shares of Rein Therapeutics worth $10K as of Q2 2022.
  • Rein Therapeutics was a new Urban Wealth Management position in Q2 2022.
  • Rein Therapeutics made up 0.03% of Urban Wealth Management's portfolio in Q2 2022, its #204 holding.
  • 37 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2022.

Based on Urban Wealth Management's 13F filing for Q2 2022, filed 22 Jul 2022.